Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen: doi:10.22028/D291-44362
Titel: Eribulin-Induced Peripheral Neuropathy in Locally Advanced or Metastatic Breast Cancer: Final Analysis of the Prospective Cohort IRENE Study
VerfasserIn: Schmidt, Marcus
Hesse, Tobias
Hoffmann, Oliver
Heinrich, Bernhard J.
Park-Simon, Tjoung-Won
Grischke, Eva-Maria
Weide, Rudolf
Müller Huesmann, Harald
Lüdtke-Heckenkamp, Kerstin
Fischer, Dorothea
Zemlin, Cosima
Kögel, Matthias
Jia, Yan
Schmitz, Helga
Engelbrecht, Christian
Jackisch, Christian
Sprache: Englisch
Titel: Cancers
Bandnummer: 17
Heft: 3
Verlag/Plattform: MDPI
Erscheinungsjahr: 2025
Freie Schlagwörter: breast neoplasms
peripheral nervous system diseases
eribulin
cohort studies
prospective studies
medical oncology
DDC-Sachgruppe: 610 Medizin, Gesundheit
Dokumenttyp: Journalartikel / Zeitschriftenartikel
Abstract: Eribulin is a preferred treatment for patients with advanced breast cancer (BC) following anthracyclines and taxanes. The final analysis of the IRENE study assessed the incidence and resolution of eribulin-induced peripheral neuropathy (EIPN), along with safety and quality of life (QoL), in patients with advanced/metastatic BC. IRENE was an observational, single-arm, prospective, multicenter cohort study. Patients aged ≥18 years with locally advanced/metastatic BC that progressed after 1–3 prior chemotherapeutic regimens received eribulin and were monitored for new-onset or worsening EIPN. Secondary endpoints included time to disease progression, safety, and health-related QoL. In total, 108 (32.2%) out of 335 patients experienced EIPN; 18 (5.4%) experienced grade ≥3 EIPN. Median time to EIPN resolution (EIPN ended or returned to baseline) was 78.7 weeks (95% CI 77.1—not estimable). Median time to disease progression was 4.5 months (95% CI 3.9–5.5). Treatment-emergent adverse events (TEAEs) occurred in 322 (96.1%) patients; serious TEAEs occurred in 185 (55.2%) patients. Incidence and resolution rates of EIPN were comparable with existing evidence from previous trials. TEAEs were consistent with the established eribulin safety profile, with no new safety signals. Eribulin treatment did not appear to affect QoL, as measured by EQ-5D-3L and EQ-VAS, or patient-reported neuropathy symptoms, as measured by the PNQ.
DOI der Erstveröffentlichung: 10.3390/cancers17030457
URL der Erstveröffentlichung: https://doi.org/10.3390/cancers17030457
Link zu diesem Datensatz: urn:nbn:de:bsz:291--ds-443620
hdl:20.500.11880/39688
http://dx.doi.org/10.22028/D291-44362
ISSN: 2072-6694
Datum des Eintrags: 18-Feb-2025
Bezeichnung des in Beziehung stehenden Objekts: Supplementary Materials
In Beziehung stehendes Objekt: https://www.mdpi.com/article/10.3390/cancers17030457/s1
Fakultät: M - Medizinische Fakultät
Fachrichtung: M - Innere Medizin
Professur: M - Keiner Professur zugeordnet
Sammlung:SciDok - Der Wissenschaftsserver der Universität des Saarlandes

Dateien zu diesem Datensatz:
Datei Beschreibung GrößeFormat 
cancers-17-00457.pdf1,46 MBAdobe PDFÖffnen/Anzeigen


Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons Creative Commons